Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration

Pharmazie

Volumn 68, Issue 1, 2013, Pages 69-74

  Cui, Xu ^a   Cao, De Ying ^a   Wang, Zhi Min ^a   Zheng, Ai Ping ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; NOSE SPRAY; VASOACTIVE INTESTINAL POLYPEPTIDE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (25 35); AMYLOID BETA-PROTEIN (25-35); IRRITANT AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CILIATED EPITHELIUM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HISTOPATHOLOGY; LATENT PERIOD; MAZE TEST; MEMORY; MEMORY DISORDER; MORPHOLOGY; MOUSE; NEUROPROTECTION; NONHUMAN; NOSE MUCOSA; SPATIAL LEARNING; TOXICITY; AEROSOL; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EUKARYOTIC FLAGELLUM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; PATHOLOGY; PSYCHOLOGICAL ASPECT; RAT; SCANNING ELECTRON MICROSCOPY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ADMINISTRATION, INTRANASAL; AEROSOLS; AMYLOID BETA-PEPTIDES; ANIMALS; CILIA; INJECTIONS, INTRAVENTRICULAR; IRRITANTS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICROSCOPY, ELECTRON, SCANNING; NASAL MUCOSA; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; VASOACTIVE INTESTINAL PEPTIDE;

MLCS; MLOWN;

EID: 84875783454     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.1148     Document Type: Article

References (16)

1. Begley DJ (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48: 136-146.
2. Cummings JL (2004) Alzheimer's disease. New Engl J Med 351: 56-67.
3. Dejda A, Sokolowska P, Nowak JZ (2005) Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep 57: 307-320.
4. Delobette S, Privat A, Maurice T (1997) In vitro aggregation facilities betaamyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharm 319: 1-4.
5. Ganea D, Delgado M (2002) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 13: 229-237.
6. GololobovG, NodaY, Sherman S, Rubinstein I, Baranowska J, Paul S (1998) Stabilization of vasoactive intestinal peptide by lipids. J Pharmacol Exp Ther 285: 753-758.
7. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci 93: 427-432.
8. Groneberg DA, Rabe KF, Fischer A (2006) Novel concepts of neuropeptide based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533: 182-194.
9. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
10. Hassan M, Refai E, Andersson M, Schnell PO, Jacobsson H (1994) In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. J Nucl Med Biol. 21: 865-872.
11. Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosine A(2a) receptor antagonists prevent betaamyloid(25-35)-induced cognitive deficits in mice. Experim Neurol 203: 241-245.
12. Mathison S, Nagilla R, Kompella UB (1998) Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 5: 415-441.
13. Pardridge WM(1999) Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technolo Today 2: 49-59.
14. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339-1346.
15. Refai E, Jonsson C, Andersson M, Jacobsson H, Larsson S, Kogner P (1999) Biodistribution of liposomal 131I-VIP in rat using gamma camera. Nucl. J Med Biol 26: 931-936.
16. Sethi V, Onyuksel H, Rubinstein I (2005) Liposomal vasoactive intestinal peptide. Methods Enzymol 391: 377-395.